177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 204 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR New on NCI’s Websites for March 2019 March 29, 2019 Immune Pathways Help Identify Patients with Cancer and HIV Most Likely... March 9, 2026 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab April 28, 2021 ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the... June 12, 2026 Load more HOT NEWS ESMO Congress 2021, 16-21 September R2-ISS: an Improved and Simple Prognostic Staging System Allows Better Stratification... ¿Puede el uso de un microondas causar cáncer? Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole...
